iTRAQ-Based Proteomics Reveals Potential Anti-Virulence Targets for ESBL-Producing Klebsiella pneumoniae

Yan Wang; Shan Cong; Qinghua Zhang; Ranwei Li; Ke Wang

doi:10.2147/IDR.S259894

iTRAQ-Based Proteomics Reveals Potential Anti-Virulence Targets for ESBL-Producing Klebsiella pneumoniae

Infect Drug Resist. 2020 Aug 19:13:2891-2899. doi: 10.2147/IDR.S259894. eCollection 2020.

Authors

Yan Wang¹, Shan Cong¹, Qinghua Zhang¹, Ranwei Li², Ke Wang¹

Affiliations

¹ Department of Respiratory and Critical Care Medicine., The Second Hospital of Jilin University, Changchun, People's Republic of China.
² Department of Urology, The Second Hospital of Jilin University, Changchun, People's Republic of China.

Abstract

Purpose: Treatment of infections with Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases (ESBLs) is challenging due to the coexistence of multiple resistance mechanisms and the hypervirulent variant. Therefore, new targets or more effective treatment options aimed at ESBL-producing Klebsiella pneumoniae are urgently needed.

Materials and methods: Here, we collected ESBL-producing and non-ESBL Klebsiella pneumoniae isolates and studied their differences from a proteomic point of view.

Results: We revealed treA, wza, gnd, rmlA, rmlC, rmlD, galE, aceE, and sucD as important virulence-related proteins in ESBL-producing Klebsiella pneumoniae, distinct from those in non-ESBL strains.

Conclusion: Our findings provide plausible anti-virulence targets and suggest new therapeutic avenues against ESBL-producing Klebsiella pneumoniae.

Keywords: Klebsiella pneumoniae; anti-virulence; extended-spectrum beta-lactamases; proteomics.